Abstract
The responsible estimation of parameters is a main issue of mathematical pandemic models. Especially a good choice of β as the number of others that one infected person encounters per unit time (per day) influences the adequateness of the results of the model. For the example of the actual COVID-19 pandemic some aspects of the parameter choice will be discussed. Because of the incompatibility of the data of the Johns-Hopkins-University [3] to the data of the German Robert-Koch-Institut we use the COVID-19 data of the European Centre for Disease Prevention and Control [2] (ECDC) as a base for the parameter estimation. Two different mathematical methods for the data analysis will be discussed in this paper and possible sources of trouble will be shown.
Parameters for several countries like UK, USA, Italy, Spain, Germany and China will be estimated and used in W. O. Kermack and A. G. McKendrick’s SIR model[1]. Strategies for the commencing and ending of social and economic shutdown measures are discussed.
The numerical solution of the ordinary differential equation system of the modified SIR model is being done with a Runge-Kutta integration method of fourth order [4].
At the end the applicability of the SIR model could be shown. Suggestions about appropriate points in time at which to commence with lockdown measures based on the acceleration rate of infections conclude the paper. This paper is an improved sequel of [5].
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There is no funding from outside. Some infrastructure of the Technical University of Berlin is used.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
I use actual data if coronavirus infected people given by the Johns-Hopkins-University
